Figure 5 | Scientific Reports

Figure 5

From: Leveraging diverse cell-death patterns to predict the prognosis, immunotherapy and drug sensitivity of clear cell renal cell carcinoma

Figure 5

Mutational and immunotherapeutic characteristic of programmed cell death signature. (A,B) Waterfall plots of somatic mutations in tumors in PRS groups; (C) Differential expression of tumor burden mutation (TMB) in PRS groups; (D) Correlation analysis among tumor burden mutation, cluster and PRS; (E) KM curve for survival difference in TMB groups; (F) KM curves for the survival difference for combination of TMB and programmed cell death related signature; (G) Differential expression of immunosuppressive checkpoints in PRS groups; (H–K) Differential expression of anti-CTLA4 and/or anti-PD1 combination immunotherapy in PRS groups.

Back to article page